151 related articles for article (PubMed ID: 16398644)
1. Stable peptide inhibitors prevent binding of lethal and oedema factors to protective antigen and neutralize anthrax toxin in vivo.
Pini A; Runci Y; Falciani C; Lelli B; Brunetti J; Pileri S; Fabbrini M; Lozzi L; Ricci C; Bernini A; Tonello F; Dal Molin F; Neri P; Niccolai N; Bracci L
Biochem J; 2006 Apr; 395(1):157-63. PubMed ID: 16398644
[TBL] [Abstract][Full Text] [Related]
2. Functional characterization of peptide-based anthrax toxin inhibitors.
Gujraty K; Sadacharan S; Frost M; Poon V; Kane RS; Mogridge J
Mol Pharm; 2005; 2(5):367-72. PubMed ID: 16196489
[TBL] [Abstract][Full Text] [Related]
3. The anthrax protective antigen (PA63) bound conformation of a peptide inhibitor of the binding of lethal factor to PA63: as determined by trNOESY NMR and molecular modeling.
Hicks RP; Bhattacharjee AK; Koser BW; Traficante DD
J Med Chem; 2004 Oct; 47(22):5347-55. PubMed ID: 15481973
[TBL] [Abstract][Full Text] [Related]
4. A soluble receptor decoy protects rats against anthrax lethal toxin challenge.
Scobie HM; Thomas D; Marlett JM; Destito G; Wigelsworth DJ; Collier RJ; Young JA; Manchester M
J Infect Dis; 2005 Sep; 192(6):1047-51. PubMed ID: 16107958
[TBL] [Abstract][Full Text] [Related]
5. Use of phage display and polyvalency to design inhibitors of protein-protein interactions.
Mourez M; Collier RJ
Methods Mol Biol; 2004; 261():213-28. PubMed ID: 15064461
[TBL] [Abstract][Full Text] [Related]
6. Human antibodies from immunized donors are protective against anthrax toxin in vivo.
Wild MA; Xin H; Maruyama T; Nolan MJ; Calveley PM; Malone JD; Wallace MR; Bowdish KS
Nat Biotechnol; 2003 Nov; 21(11):1305-6. PubMed ID: 14555959
[TBL] [Abstract][Full Text] [Related]
7. Designing a polyvalent inhibitor of anthrax toxin.
Mourez M; Kane RS; Mogridge J; Metallo S; Deschatelets P; Sellman BR; Whitesides GM; Collier RJ
Nat Biotechnol; 2001 Oct; 19(10):958-61. PubMed ID: 11581662
[TBL] [Abstract][Full Text] [Related]
8. EMILINs interact with anthrax protective antigen and inhibit toxin action in vitro.
Doliana R; Veljkovic V; Prljic J; Veljkovic N; De Lorenzo E; Mongiat M; Ligresti G; Marastoni S; Colombatti A
Matrix Biol; 2008 Mar; 27(2):96-106. PubMed ID: 17988845
[TBL] [Abstract][Full Text] [Related]
9. Activity of the Bacillus anthracis 20 kDa protective antigen component.
Hammamieh R; Ribot WJ; Abshire TG; Jett M; Ezzell J
BMC Infect Dis; 2008 Sep; 8():124. PubMed ID: 18808698
[TBL] [Abstract][Full Text] [Related]
10. Neutralizing monoclonal antibody against anthrax lethal factor inhibits intoxication in a mouse model.
Zhao P; Liang X; Kalbfleisch J; Koo HM; Cao B
Hum Antibodies; 2003; 12(4):129-35. PubMed ID: 15156101
[TBL] [Abstract][Full Text] [Related]
11. Selection of human antibodies against cell surface-associated oligomeric anthrax protective antigen.
Steiniger SC; Altobell LJ; Zhou B; Janda KD
Mol Immunol; 2007 Apr; 44(10):2749-55. PubMed ID: 17210180
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of immunodominant B-cell epitope of the C-terminus of protective antigen of Bacillus anthracis.
Kaur M; Chug H; Singh H; Chandra S; Mishra M; Sharma M; Bhatnagar R
Mol Immunol; 2009 Jun; 46(10):2107-15. PubMed ID: 19356802
[TBL] [Abstract][Full Text] [Related]
13. Anthrax X-rayed: new opportunities for biodefence.
Stubbs MT
Trends Pharmacol Sci; 2002 Dec; 23(12):539-41. PubMed ID: 12457764
[TBL] [Abstract][Full Text] [Related]
14. Anthrax oedema toxin induces anthrax toxin receptor expression in monocyte-derived cells.
Maldonado-Arocho FJ; Fulcher JA; Lee B; Bradley KA
Mol Microbiol; 2006 Jul; 61(2):324-37. PubMed ID: 16856939
[TBL] [Abstract][Full Text] [Related]
15. Fusion protein of Delta 27LFn and EFn has the potential as a novel anthrax toxin inhibitor.
Kong Y; Guo Q; Yu C; Dong D; Zhao J; Cai C; Hou L; Song X; Fu L; Xu J; Chen W
FEBS Lett; 2009 Apr; 583(8):1257-60. PubMed ID: 19332063
[TBL] [Abstract][Full Text] [Related]
16. Beta-cyclodextrin derivatives that inhibit anthrax lethal toxin.
Karginov VA; Yohannes A; Robinson TM; Fahmi NE; Alibek K; Hecht SM
Bioorg Med Chem; 2006 Jan; 14(1):33-40. PubMed ID: 16169738
[TBL] [Abstract][Full Text] [Related]
17. Hydrophobic residues Phe552, Phe554, Ile562, Leu566, and Ile574 are required for oligomerization of anthrax protective antigen.
Ahuja N; Kumar P; Bhatnagar R
Biochem Biophys Res Commun; 2001 Sep; 287(2):542-9. PubMed ID: 11554763
[TBL] [Abstract][Full Text] [Related]
18. New insights into the functions of anthrax toxin.
Banks DJ; Ward SC; Bradley KA
Expert Rev Mol Med; 2006 Apr; 8(7):1-18. PubMed ID: 16608555
[TBL] [Abstract][Full Text] [Related]
19. Interactions between anthrax toxin receptors and protective antigen.
Scobie HM; Young JA
Curr Opin Microbiol; 2005 Feb; 8(1):106-12. PubMed ID: 15694864
[TBL] [Abstract][Full Text] [Related]
20. Screening inhibitors of anthrax lethal factor.
Tonello F; Seveso M; Marin O; Mock M; Montecucco C
Nature; 2002 Jul; 418(6896):386. PubMed ID: 12140548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
